Cargando…

Infused autograft lymphocyte to monocyte ratio predicts survival in classical Hodgkin lymphoma

The infused autograft lymphocyte to monocyte ratio (A-LMR) as a surrogate marker of host immunity (ie, absolute lymphocyte count) and CD14+ HLA-DR(low/neg) immunosuppressive monocytes (ie, absolute monocyte count) is a prognostic factor for patients with diffuse large B-cell lymphoma after autologou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Porrata, Luis F, Inwards, David J, Ansell, Stephen M, Micallef, Ivana N, Johnston, Patrick B, Hogan, William J, Markovic, Svetomir N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321658/ https://www.ncbi.nlm.nih.gov/pubmed/25674021 http://dx.doi.org/10.2147/JBM.S75784

Ejemplares similares

Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation
por: Porrata, Luis F., et al.
Publicado: (2015)

Day 100 Peripheral Blood Absolute Lymphocyte/Monocyte Ratio and Survival in Classical Hodgkin's Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation
por: Porrata, Luis F., et al.
Publicado: (2013)

Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma
por: Porrata, L F, et al.
Publicado: (2013)

Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas
por: Porrata, Luis F., et al.
Publicado: (2010)

Long‐term outcome of immunologic autograft engineering
por: Porrata, Luis F., et al.
Publicado: (2022)

Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma
por: Holtan, Shernan G, et al.
Publicado: (2006)

Dendritic cell vaccine treatment for indolent B cell non-hodgkin lymphoma: clinical trial in progress
por: Lin, Yi, et al.
Publicado: (2014)

Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant
por: Tun, Aung M., et al.
Publicado: (2023)

Assessment of the Neutrophil-Lymphocyte Ratio in Classic Hodgkin Lymphoma Patients
por: Dogan, Ali, et al.
Publicado: (2019)

Impact on the survival of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and monocyte-lymphocyte ratio on prognosis in children with Hodgkin lymphoma
por: Ertan, Kubra, et al.
Publicado: (2022)

Prognostic significance of lymphocyte-to-monocyte ratio in patients with classical Hodgkin lymphoma before and after receiving first-line chemotherapy
por: Taha, Heba F., et al.
Publicado: (2022)

An updated portrait of monocyte-macrophages in classical Hodgkin lymphoma
por: Ferrarini, Isacco, et al.
Publicado: (2023)

The Impact of Infused Autograft Absolute Numbers of Immune Effector Cells on Survival Post-Autologous Stem Cell Transplantation
por: Porrata, Luis F.
Publicado: (2022)

Prognostic value of lymphocyte-monocyte ratio at diagnosis in Hodgkin lymphoma: a meta-analysis
por: Lee, Shing Fung, et al.
Publicado: (2019)

CD34(+) cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies
por: Holtan, S G, et al.
Publicado: (2010)

Chronic lymphocytic leukemia (CLL) with Reed–Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?
por: King, Rebecca L., et al.
Publicado: (2022)

Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study
por: Desai, Sanjal H., et al.
Publicado: (2021)

Identification of a novel monocytic phenotype in Classic Hodgkin Lymphoma tumor microenvironment
por: Post, Ginell R., et al.
Publicado: (2019)

Predicting Peripheral Blood Stem Cell Harvest Failure Using Circulating CD34 Levels: Developing Target-Based Cut-Points for Early Intervention
por: Sinha, S, et al.
Publicado: (2010)

End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET
por: Chohan, Karan L., et al.
Publicado: (2022)

Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma
por: Wang, Yucai, et al.
Publicado: (2018)

IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low/−) monocytes in B-cell non-Hodgkin lymphoma
por: Xiu, B, et al.
Publicado: (2015)

Genetics of classical Hodgkin Lymphoma
por: Schiavoni, Gianluca, et al.
Publicado: (2018)

A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome
por: Chohan, Karan L., et al.
Publicado: (2022)

Monocyte-to-Lymphocyte Ratio in the Diagnosis of Lymphoma in Adult Patients
por: Kamiya, Naoko, et al.
Publicado: (2022)

Prognostic Value of Peripheral Blood Lymphocyte/monocyte Ratio in Lymphoma
por: Gao, Feiqiong, et al.
Publicado: (2021)

The molecular mechanisms of classic Hodgkin's lymphoma.
por: Felberbaum, Rachael S.
Publicado: (2005)

Immunological Deregulation in Classic Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2014)

Controversies in the Treatment of Classical Hodgkin Lymphoma
por: Eichenauer, Dennis A., et al.
Publicado: (2018)

The Grey Zones of Classic Hodgkin Lymphoma
por: Bosch-Schips, Jan, et al.
Publicado: (2022)

Composite follicular lymphoma and classic Hodgkin lymphoma
por: Kim, Han-Na, et al.
Publicado: (2022)

Hemophagocytic Lymphohistiocytosis in a Patient with Classical Hodgkin Lymphoma
por: Hyun, G., et al.
Publicado: (2016)

Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
por: Johnston, Patrick B., et al.
Publicado: (2018)

The real risk of secondary non-Hodgkin lymphoma following classical Hodgkin lymphoma
por: Dogan, Ahmet
Publicado: (2022)

Neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and platelet-to-lymphocyte ratio in different etiological causes of thyrotoxicosis
por: TAŞKALDIRAN, Işılay, et al.
Publicado: (2019)

Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and platelet to lymphocyte ratio to predict the severity of COVID-19
por: Seyit, Murat, et al.
Publicado: (2021)

Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and platelet to lymphocyte ratio to predict the severity of COVID-19
por: Seyit, Murat, et al.
Publicado: (2021)

Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients
por: Saeed, L, et al.
Publicado: (2017)

High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)
por: Witzig, T E, et al.
Publicado: (2017)

Prognostic value of lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio in follicular lymphoma: a retrospective cohort study
por: Lee, Shing Fung, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_usj6f7fnilgbegl8iqe8sq16t2